Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Show account info Close Account (...) Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Circulation Actions . 2021 Feb 9;143(6):540-552. doi: 10.1161/CIRCULATIONAHA.120.051898. Epub 2020 Nov 16. Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes , , , , , , , , , , , Affiliations Expand Affiliations 1 National and Kapodistrian University of Athens, School of Medicine, Department of Cardiology, Attikon University Hospital, Greece

Tyrosine kinase inhibitors in chronic myeloid leukaemia and emergent cardiovascular disease Tyrosine kinase inhibitors in chronic myeloid leukaemia and emergent cardiovascular disease - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. National Institutes of Health National Library (...) Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Heart Actions . 2021 Jan 8;heartjnl-2020-318251. doi: 10.1136/heartjnl-2020-318251. Online ahead of print. Tyrosine kinase inhibitors in chronic myeloid leukaemia and emergent cardiovascular disease , , , , , , , Affiliations Expand Affiliations 1 Population Health Research Institute, McMaster University and Hamilton

Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly (...) Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Circulation Actions . 2021 Feb 2;143(5):438-448. doi: 10.1161/CIRCULATIONAHA.120.051675. Epub 2020 Nov 13. Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease

Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set (...) options Format Share Permalink Copy Page navigation Lancet Diabetes Endocrinol Actions . 2021 Jan;9(1):22-31. doi: 10.1016/S2213-8587(20)30369-7. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Department of Renal Medicine, University College London, London, UK; The George Institute for Global Health

Somethin’ Fishy: Prescription variants of Omega-3 to prevent cardiovascular disease November 16, 2020 Somethin’ Fishy: Prescription variants of Omega-3 to prevent cardiovascular disease Clinical Question: Do prescription variants of omega-3’s, like icosapent, reduce the risk of cardiovascular events when added to statins? Bottom Line: In high risk patients, icosapent reduced cardiovascular events to 17% from 22% on placebo after 5 years. In lower risk patients, Eicosapentaenoic Acid (EPA) ethyl (...) of cardiovascular disease 4,5 particularly when examining high quality studies. 5 • Evidence gaps include: o A small secondary prevention trial has not been published. 6 o Additional trials evaluating EPA on cardiovascular outcomes are not being conducted. 7 o No studies compare EPA products. o Concerns exist with approving medications on single trial results. 8 • Only icosapent is approved in Canada. 9 o Cost (~$3600/year) requires >40% reduction to approach cost effectiveness. 10 Authors: Allison Paige MD

What is the effectiveness of systematic population-level screening programmes for reducing the burden of cardiovascular diseases? I WHO HEALTH EVIDENCE NETWORK SYNTHESIS REPORT 71 What is the effectiveness of systematic population-level screening programmes for reducing the burden of cardiovascular diseases? Christian Ulrich Eriksen | Oxana Rotar | Ulla Toft | Torben JørgensenThe Health Evidence Network The Health Evidence Network (HEN) is an information service for public health decision (...) for Europe has three main functions: leading the integrated response of policies to address noncommunicable diseases (NCDs) at the regional and country levels; managing the major NCDs (cardiovascular diseases, cancer, chronic respiratory diseases and diabetes) across the continuum of care from prevention to early detection, screening, diagnosis, treatment, rehabilitation, secondary prevention and end-of-life/palliative care; and leading the NCD health systems response. It focuses on priority action areas

Associations of Late Adolescent or Young Adult Cardiovascular Health With Premature Cardiovascular Disease and Mortality Associations of Late Adolescent or Young Adult Cardiovascular Health With Premature Cardiovascular Disease and Mortality - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving (...) . Associations of Late Adolescent or Young Adult Cardiovascular Health With Premature Cardiovascular Disease and Mortality , , , , , , , , Affiliations Expand Affiliations 1 Department of Preventive Medicine, Northwestern University, Chicago, Illinois; Department of Pediatrics, Northwestern University, Chicago, Illinois. Electronic address: amarma@luriechildrens.org. 2 Department of Preventive Medicine, Northwestern University, Chicago, Illinois. 3 Department of Preventive Medicine, Northwestern University

Healthy Diet and Physical Activity for Cardiovascular Disease Prevention in Adults With Cardiovascular Risk Factors: Behavioral Counseling Interventions Recommendation | United States Preventive Services Taskforce Toggle navigation Main navigation Main navigation Recommendation to see the latest documents available. Recommendation Summary Population Recommendation Adults who are overweight or obese and have additional CVD risk factors The USPSTF recommends offering or referring adults who (...) are overweight or obese and have additional cardiovascular disease (CVD) risk factors to intensive behavioral counseling interventions to promote a healthful diet and physical activity for CVD prevention. B View the Clinical Summary in Population Adults in primary care who are overweight or obese and have known cardiovascular risk factors Recommendation Offer or refer to intensive behavioral counseling interventions to promote a healthful diet and physical activity. Grade: B Risk Assessment Well-established

Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association | Circulation Search Search Hello Guest! Login to your account Email Password Keep me logged in Search Search December 2020 November 2020 October 2020 September 2020 August 2020 July (...) 2020 June 2020 May 2020 April 2020 March 2020 February 2020 January 2020 This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access Review Article Share on Jump to Free Access Review Article Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association , PhD, MPH, FAHA, Chair , EdD, MS, FAHA , PhD, FAHA , MD, FAHA , MD, MS, MBA , MD, MPH, FAHA , MD, FAHA

. (EARL) has established a standard ( , ) for intercenter harmonization for [ 18 F]FDG imaging. A standard for PET/CT imaging in inflammatory, infective, infiltrative, and innervation dysfunctional (4Is) cardiovascular diseases is currently lacking. Therefore, standards for PET imaging not limited to FDG are needed specifically designed for cardiovascular disorders. Goals The purpose of this document is to assist in performing PET/CT and PET/MR for cardiovascular imaging in the field of 4Is, starting (...) Procedural recommendations of cardiac PET/CT imaging: standardization in inflammatory-, infective-, infiltrative-, and innervation (4Is)-related cardiovascular diseases: a joint collaboration of the EACVI and the EANM Procedural recommendations of cardiac PET/CT imaging: standardization in inflammatory-, infective-, infiltrative-, and innervation (4Is)-related cardiovascular diseases: a joint collaboration of the EACVI and the EANM | SpringerLink Search Search SpringerLink Search Procedural

Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set (...) options Format Share Permalink Copy Page navigation Randomized Controlled Trial Lancet Diabetes Endocrinol Actions . 2020 Dec;8(12):949-959. doi: 10.1016/S2213-8587(20)30344-2. Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Division of Cardiology, Department of Internal Medicine, University

Association of beta-blocker use with survival and pulmonary function in patients with chronic obstructive pulmonary and cardiovascular disease: a systematic review and meta-analysis Association of β-blocker use with survival and pulmonary function in patients with chronic obstructive pulmonary and cardiovascular disease: a systematic review and meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard (...) Share Permalink Copy Page navigation Eur Heart J Actions . 2020 Nov 19;ehaa793. doi: 10.1093/eurheartj/ehaa793. Online ahead of print. Association of β-blocker use with survival and pulmonary function in patients with chronic obstructive pulmonary and cardiovascular disease: a systematic review and meta-analysis , , , , , Affiliations Expand Affiliations 1 Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union

Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving (...) and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis , , , , , , , Affiliations Expand Affiliations 1 Departamento de Medicina Preventiva, Escola Paulista de Medicina, Universidade Federal de São Paulo, Rua Botucatu, n° 740, Vila Clementino, São Paulo, SP CEP 04023-062 Brazil. 2 Sociedade Brasileira de Diabetes-SBD, Rua Afonso Braz, 579, Salas 72/74, Vila Nova Conceição, São Paulo, SP CEP 04511-011 Brazil. 3 Programa de Pós-Graduação Em Endocrinologia

Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study - PubMed This site needs JavaScript (...) RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Diabetes Obes Metab Actions . 2020 Sep 7. doi: 10.1111/dom.14189. Online ahead of print. Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Oslo

plots and tabular presentations was performed. Associations for composite cardiovascular disease were: twofold for pre-eclampsia, stillbirth, and preterm birth; 1.5-1.9-fold for gestational hypertension, placental abruption, gestational diabetes, and premature ovarian insufficiency; and less than 1.5-fold for early menarche, polycystic ovary syndrome, ever parity, and early menopause. A longer length of breastfeeding was associated with a reduced risk of cardiovascular disease. The associations (...) contraceptives or progesterone only pill), pre-eclampsia, and recurrent pre-eclampsia; 1.5-1.9-fold for current use of combined oral contraceptives, gestational diabetes, and preterm birth; and less than 1.5-fold for polycystic ovary syndrome. The association for heart failure was fourfold for pre-eclampsia. No association was found between cardiovascular disease outcomes and current use of progesterone only contraceptives, use of non-oral hormonal contraceptive agents, or fertility treatment.From menarche

Thyroid Dysfunction and cardiovascular events in patients with chronic kidney disease: A protocol of systematic review and meta-analysis Inplasy Protocol 856 - INPLASY.COM International Platform of Registered Systematic Review and Meta-analysis Protocols Main Menu Share this: Copyright © 2021 INPLASY.COM Powered by INPLASY.COM

in the elderly, immunosuppressed, and those with cardiovascular comorbidities. Therefore, a better understanding of these findings is needed. A systematic review was carried out looking for articles published between December 2019 and May 2020 on the MEDLINE / PubMed search platform using the following descriptors : ((((((((("cardiovascular disease") OR ("acute myocardial infarction")) OR ("coronary artery disease")) OR ("acute coronary syndrome")) OR ("atherosclerosis")) OR ("cardiac insufficiency (...) , immunosuppressed, and those with cardiovascular comorbidities. Therefore, a better understanding of these findings is needed. A systematic review was carried out looking for articles published between December 2019 and May 2020 on the MEDLINE / PubMed search platform using the following descriptors : ((((((((("cardiovascular disease") OR ("acute myocardial infarction")) OR ("coronary artery disease")) OR ("acute coronary syndrome")) OR ("atherosclerosis")) OR ("cardiac insufficiency")) OR ("pericarditis

Omega-3 supplementation and cardiovascular disease: formulation-based systematic review and meta-analysis with trial sequential analysis Omega-3 supplementation and cardiovascular disease: formulation-based systematic review and meta-analysis with trial sequential analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 (...) ahead of print. Omega-3 supplementation and cardiovascular disease: formulation-based systematic review and meta-analysis with trial sequential analysis # , # , , , Affiliations Expand Affiliations 1 Department of Internal Medicine, University Hospital of Ioannina, Ioannina, Greece. 2 School of Medicine, European University of Cyprus, Nicosia, Cyprus. 3 Evidence-Based Medicine Unit, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece. 4 Clinical

Cost-effectiveness of cardiovascular imaging for stable coronary heart disease Cost-effectiveness of cardiovascular imaging for stable coronary heart disease - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest public health information from CDC: . Get the latest (...) new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Heart Actions . 2020 Aug 14;heartjnl-2020-316990. doi: 10.1136/heartjnl-2020-316990. Online ahead of print. Cost-effectiveness of cardiovascular imaging for stable coronary heart disease

Evaluating the value of apolipoprotein B testing for the assessment and management of atherosclerotic cardiovascular disease at the MUHC RUISSS Report available at https://muhc.ca/tau Technology Assessment Unit of the McGill University Health Centre (MUHC) Evaluating the value of apolipoprotein B testing for the assessment and management of atherosclerotic cardiovascular disease at the MUHC RUISSS Report number: 84 DATE: May 14 th , 2020 Report available at https://muhc.ca/tau Report prepared (...) cardiovascular disease at the MUHC RUISSS. Montreal (Canada): Technology Assessment Unit (TAU) of the McGill University Health Centre (MUHC); 2020 May 14. Report no. 84. 64 pagesApoB iii 14 May 2020 Technology Assessment Unit, MUHC ACKNOWLEDGEMENTS The expert assistance of the following individuals is gratefully acknowledged: ? David Blank, MUHC Site Chief, Division of Biochemistry, Department of Clinical Laboratory Medicine, MUHC ? Allan Sniderman, Cardiologist at the MUHC and Senior Scientist